期刊文献+

利拉鲁肽对糖耐量异常OLETF大鼠糖脂代谢及骨代谢的影响 被引量:3

Influences of liraglutide on glycolipid and bone metabolism in OLETF rats with impaired glucose tolerance
下载PDF
导出
摘要 目的:观察利拉鲁肽对糖耐量异常OLETF大鼠糖脂代谢及骨代谢的影响。方法 :32只12周龄糖耐量异常的OLETF大鼠随机分为生理盐水组和不同剂量利拉鲁肽干预组(50、100、200μg/kg),8只同种系LETO大鼠作为正常对照组。实验结束时,所有大鼠均检测糖脂及骨代谢指标。结果:生理盐水组OLETF大鼠与LETO组相比,血糖、总胆固醇、甘油三酯升高(P<0.05),骨钙素及降钙素差异无显著性;利拉鲁肽干预后,血糖、总胆固醇、甘油三酯降低,骨钙素、降钙素升高。结论:利拉鲁肽能够改善自发糖耐量异常动物模型糖脂代谢及骨代谢状况,促进骨形成,抑制骨吸收,延缓或预防高糖所致的骨质恶化。 Objective To investigate the effects of liraglutide on glucose,lipid and bone metabolism in OLETF rats with impaired glucose tolerance(IGT).Methods 32 twelve-week-old OLETF rats were randomized into 4 groups and received normal saline(NS group) or 50,100,or 200 μg / kg of liraglutide for 12 weeks,respectively.8 LETO rats served as controls and received normal saline(LETO group).After the treatment,parameters about glucose,lipid and bone metabolism were examined.Results Compared with LETO group,fasting blood glucose(FBG),total cholesterol(TC),triglyceride(TG) were increased in NS group(P 0.05),while osteocalcin and calcitonin had no significant difference.After administered by liraglutide,FBG,TC,and TG of rats were decreased,while osteocalcin and calcitonin were increased.Conclusions Liraglutide can improve glucose,lipid and bone metabolism in OLETF rats.
出处 《实用医学杂志》 CAS 北大核心 2013年第10期1573-1575,共3页 The Journal of Practical Medicine
基金 中华国际医学交流基金会资助项目(编号:2100325) 国家自然科学基金资助项目(编号:81270966) 广东省自然科学基金资助项目(编号:S2012010009494)
关键词 利拉鲁肽 糖耐量异常 OLETF大鼠 骨形成 骨吸收 Liraglutide Impaired glucose tolerance OLETF rats Bone formation Bone resorption
  • 相关文献

参考文献9

  • 1Nuche-Berenguer B, Moreno P, Esbrit P, et al. Effect of GLP- 1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states [J]. Calcif Tissue Int, 2009, 84(6): 453-461. 被引量:1
  • 2Nuche-Berenguer B, Moreno P, Portal-Nufiez S, et al. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states [J]. Regulator) Peptides, 2010, 159(1-3) : 61-66. 被引量:1
  • 3Yamada C, Yamada Y, Tsukiyama K, et al. The murine glueagon-like peptide-1 receptor is essential for control of bone resorption [ J ]. Endocrinology, 2008, 149(2) : 574-579. 被引量:1
  • 4Duarte VM, Ramos AM, Rezende LA, et al. Osteopenia: a bone disorder associated with diabetes mellitus [J]. J Bone Miner Metab, 2005, 23 ( 1 ) : 58-68. 被引量:1
  • 5郭南京,孙嘉,陈宏,徐艳花,高飞,张桦,张振,蔡德鸿.利拉鲁肽对糖耐量异常OLETF大鼠胰岛白细胞介素-1β表达的影响[J].南方医科大学学报,2012,32(6):878-881. 被引量:11
  • 6Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients [J]. Diabetes, 2001, 50(3): 609-613. 被引量:1
  • 7Nuche-Berenguer B, Portal-Ntfiez S, Moreno P, et al. Presence of a Functional Receptor for GLP-1 in Osteoblastic Cells,Independent of the cAMP-Linked GLP-1 Receptor [J]. J Cell Physiol, 2010,225(2) : 585-592. 被引量:1
  • 8Sanz C, V6zquez P, BlOzquez C, et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow [J]. Am J Physiol Endocrinol Metab, 2010, 298(3): E634-643. 被引量:1
  • 9Clabaut A,Delplace S,Chauveau C,et al. Human osteoblasts derived from mesenchymal stem cells express adipogenic markers upon coculture with bone marrow adipocytes [J]. Differentiation, 2010, 80( 1 ) :40-45. 被引量:1

二级参考文献12

  • 1Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-lbeta in type 2 diabetes[J]. Curr Opin Endoerinol Diabetes Obes, 2010, 17 (4): 314-21. 被引量:1
  • 2Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes[J]. Drug Des Devel Ther, 2010, 4: 279-90. 被引量:1
  • 3Courr+ges JP, Vilsbφll T, Zdravkovic M, et al. Beneficial effects of once-daily liraglutide, a human glucagon-likc peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes [J]. Diabet Med, 2008, 25(9): 1129-3l. 被引量:1
  • 4Kawano K, Hirashima T, Mori S, et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty(OLETF)strain[J]. Diabetes, 1992, 41 (11): 1422-8. 被引量:1
  • 5Cechin SR, Perez-Alvarez I, Fenjves E, et al. Anti-Inflammatory properties of exenatide in human pancreatic islets [J]. Cell Transplant, 2011. [Epub ahead of print]. 被引量:1
  • 6Pour OR, Dagogo-Jack S. Prediabetes as a therapeutic target [J]. Clin Chem, 2011, 57(2): 215-20. 被引量:1
  • 7Okopien B, Stachura-Kulach A, Kulach A, et al. The risk of atherosclerosis in patients with impaired glucose tolerance [J]. Res Commun Mol Pathol Pharrnacol, 2003, 113-114: 87-95. 被引量:1
  • 8Muller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors [J]. Diabetologia, 2002, 45(6): 805-12. 被引量:1
  • 9Maedler K, Dharmadhikari G, Schumann DM, et al. Interleukin-1 beta targeted therapy for type 2 diahetes[J]. Expert Opin Biol Ther, 2009, 9(9): 1177-88. 被引量:1
  • 10Yban'a J, Lehmann TN, Golay A, et al. Gender-based dimorphic pattern for interleukin-I receptor antagonist in type 2 diabetes mellitus [J]. Diabetes Metab, 2008, 34(1): 75-81. 被引量:1

共引文献10

同被引文献40

  • 1程晓光(译),刘忠厚(校).国际临床骨密度学会共识文件(2005年版)[J].中国骨质疏松杂志,2006,12(2):205-209. 被引量:68
  • 2Yamada C, Yamada Y, Tsukiyama K, et al The murine glucagon- like peptide-1 receptor is essential for control of bone resorp- tion. Endocrinology, 2008, 149: 574-579. 被引量:1
  • 3Nuche-Berenguer B, Moreno P, Eshrit P, et al. Effect of GIY-1 treatment on bone turnover in normal, type 2 diabetic, and in- sulin-resistant states. Calcif Tissue lnt, 2009, 84: 453-461. 被引量:1
  • 4Nuche-Berenguer B, Moreno P, Portal-Nunez S, et al. Exendin-4 exerts osteogenic actions in insulin-resistant an, type 2 diabetic states. Regul Pept, 2010, 159: 61-66. 被引量:1
  • 5Kyle KA, Willett TL, Baggio LL, et al. Differential effects of PPAR-gamma activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice. Endocrinology 2011, 152: 457-467. 被引量:1
  • 6Bunck MC,Eliasson B,Corn6r A, et al. Exenatide treatmen: did not affect bone mineral density despite body weight reduc tion in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13: 374-377. 被引量:1
  • 7Bunck MC, Poelma M, Eekhoff EM, et al. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes, 2012, 4:181-185. 被引量:1
  • 8Monami M, Dicembrini I, Antenore A, et al. Dipeptidyl pepti- dase-4 inhibitors and bone fractures: a meta-analysis of ran- domized clinical trials. Diabetes Care, 2011,34:2474-2476. 被引量:1
  • 9Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, et al. Receptors and effects of gut hormones in three osteoblastic cell lines. BMC Physiol, 2011, 11:12. 被引量:1
  • 10Sanz C, Vazquez P, Blazquez C, et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mes- enchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab, 2010, 298:E634-E643. 被引量:1

引证文献3

二级引证文献76

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部